Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Lasers Med Sci ; 39(1): 172, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38965092

RÉSUMÉ

The study utilized 5-ALA-PDT to treat patients with CIN or VaIN and assessed their clinical response, HPV clearance, and influencing factors after photodynamic therapy (PDT). This study involved 56 patients who received 5-ALA-PDT in a single center from May 2020 to March 2022, including 12 patients with CIN, 30 patients with VaIN, and 14 patients with both CIN and VaIN. Follow-up were conducted within 6 and 12 months after treatment to evaluate the clinical effectiveness of PDT. The assessment criteria included histological response (ER, elimination rate, RR, regression rate) and HPV clearance. Additionally, factors that could potentially influence the outcomes were analyzed. After PDT, the histological response showed an ER of 48.2% (27/56) and a RR of 80.4% (45/56) within 6 months of follow-up. The elimination rate increased to 69.6% (39/56) within 12 months, along with a regression rate of 82.1% (46/56). The rates of HPV clearance were observed to be 37.5% (21/56) and 44.6% (25/56) within 6 and 12 months, respectively. The study also revealed that HPV clearance significantly influenced histologic elimination within 6 months (p < 0.001) and histologic regression within 12 months (p < 0.01). Furthermore, premenopausal women exhibited a higher HPV clearance rate compared to postmenopausal women (61.5% vs. 30.0%, p = 0.036). 5-ALA PDT can be considered as an available option for the treatment of lower genital squamous intraepithelial lesions. The efficacy of its histologic response depends on HPV clearance. Additionally, it has been found that premenopausal women may benefit more from this treatment.


Sujet(s)
Acide amino-lévulinique , Photothérapie dynamique , Photosensibilisants , Humains , Femelle , Photothérapie dynamique/méthodes , Acide amino-lévulinique/usage thérapeutique , Acide amino-lévulinique/administration et posologie , Adulte , Photosensibilisants/usage thérapeutique , Photosensibilisants/administration et posologie , Adulte d'âge moyen , Résultat thérapeutique , Dysplasie du col utérin/traitement médicamenteux , Dysplasie du col utérin/virologie , Dysplasie du col utérin/anatomopathologie , Infections à papillomavirus/traitement médicamenteux , Infections à papillomavirus/virologie , Tumeurs du col de l'utérus/traitement médicamenteux , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/anatomopathologie , Jeune adulte , Sujet âgé
2.
Clin Epigenetics ; 16(1): 77, 2024 Jun 07.
Article de Anglais | MEDLINE | ID: mdl-38849868

RÉSUMÉ

OBJECTIVE: The major challenge in routine endocervical curettage (ECC) among Human Papillomavirus (HPV) 16/18-positive patients is that only a small fraction benefit. Nevertheless, current reported models often overestimate the validity and necessity of ECC, making it difficult to improve benefits for patients. This research hypothesized that assessing paired boxed gene 1 methylation levels (PAX1m) and clinical characteristics could enhance the predictive accuracy of detecting additional high-grade squamous intraepithelial lesions or worse (HSIL +) through ECC that were not identified by colposcopy-directed biopsy (CDB). METHODS: Data from 134 women with HPV16/18 positivity undergoing CDB and ECC between April 2018 and April 2022 were collected and analyzed. Quantitative methylation-specific polymerase chain reaction (qMSP) was utilized to measure PAX1m, expressed as ΔCp. Univariate and multivariate regression analyses were conducted to screen variables and select predictive factors. A nomogram was constructed using multivariate logistic regression to predict additional HSIL + detected by ECC. The discrimination, calibration, and clinical utility of the nomogram were evaluated using receiver operating characteristic curves (ROC) and the calibration plot. RESULTS: Age (odds ratio [OR], 5.654; 95% confidence interval [CI], 1.131-37.700), cytology (OR, 24.978; 95% CI, 3.085-540.236), and PAX1 methylation levels by grade (PAX1m grade) (OR, 7.801; 95% CI, 1.548-44.828) were independent predictive factors for additional detection of HSIL + by ECC. In HPV16/18-positive women, the likelihood of additional detection of HSIL + through ECC increased with the severity of cytological abnormalities, peaking at 43.8% for high-grade cytological lesions. Moreover, when cytological findings indicated low-grade lesions, PAX1 methylation levels were positively correlated with the additional detection of HSIL + by ECC (P value < 0.001). A nomogram prediction model was developed (area under curve (AUC) = 0.946; 95% CI, 0.901-0.991), demonstrating high sensitivity (90.9%) and specificity (90.5%) at the optimal cutoff point of 107. Calibration analysis confirmed the model's strong agreement between predicted and observed probabilities. CONCLUSION: The clinical nomogram presented promising predictive performance for the additional detection of HSIL + through ECC among women with HPV16/18 infection. PAX1 methylation level could serve as a valuable tool in guiding individualized clinical decisions regarding ECC for patients with HPV 16/18 infection, particularly in cases of low-grade cytological findings.


Sujet(s)
Colposcopie , Méthylation de l'ADN , Papillomavirus humain de type 16 , Papillomavirus humain de type 18 , Nomogrammes , Facteurs de transcription PAX , Infections à papillomavirus , Tumeurs du col de l'utérus , Humains , Femelle , Facteurs de transcription PAX/génétique , Papillomavirus humain de type 16/génétique , Papillomavirus humain de type 16/isolement et purification , Adulte , Méthylation de l'ADN/génétique , Adulte d'âge moyen , Papillomavirus humain de type 18/génétique , Papillomavirus humain de type 18/isolement et purification , Infections à papillomavirus/diagnostic , Infections à papillomavirus/génétique , Infections à papillomavirus/virologie , Tumeurs du col de l'utérus/génétique , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/diagnostic , Tumeurs du col de l'utérus/anatomopathologie , Curetage/méthodes , Courbe ROC , Dysplasie du col utérin/virologie , Dysplasie du col utérin/génétique , Dysplasie du col utérin/diagnostic , Dysplasie du col utérin/anatomopathologie , Col de l'utérus/anatomopathologie , Col de l'utérus/virologie
3.
J Pediatr Adolesc Gynecol ; 35(3): 407-409, 2022 Jun.
Article de Anglais | MEDLINE | ID: mdl-35032667

RÉSUMÉ

BACKGROUND: Ovarian granulosa cell tumor (GCT) is extremely rare in children and adolescents, especially along with Meigs syndrome (MS). CASE: We describe the case of a 12-year-old girl who was referred to our center for massive peritoneal effusions with evidence of a pelvic mass on ultrasonography and computed tomography. The patient was treated with laparoscopic surgery (fertility-sparing surgery) and postoperative chemotherapy. SUMMARY AND CONCLUSION: Our case highlights the clinical importance of assessing MS in the diagnosis of pediatric female patients with peritoneal effusion and ovarian mass and the importance of fertility-sparing surgery.


Sujet(s)
Tumeur de la granulosa , Laparoscopie , Syndrome de Meigs , Tumeurs de l'ovaire , Adolescent , Enfant , Femelle , Tumeur de la granulosa/complications , Tumeur de la granulosa/imagerie diagnostique , Tumeur de la granulosa/chirurgie , Humains , Laparoscopie/effets indésirables , Syndrome de Meigs/diagnostic , Syndrome de Meigs/étiologie , Syndrome de Meigs/chirurgie , Tumeurs de l'ovaire/complications , Tumeurs de l'ovaire/imagerie diagnostique , Tumeurs de l'ovaire/chirurgie , Tomodensitométrie/effets indésirables
4.
ACS Omega ; 4(18): 17798-17806, 2019 Oct 29.
Article de Anglais | MEDLINE | ID: mdl-31681886

RÉSUMÉ

Polymers 4 containing poly(arylene ethynylene) were synthesized and characterized systematically. Among them, 4c exhibited a remarkable H2 evolution rate (14.32 mmol h-1 g-1) with visible-light irradiation, lasting 72 h in different water qualities; the corresponding apparent quantum yield was 11.6% at 450 nm.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...